GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio
GE HealthCare (GEHC) has received FDA 510(k) clearance for three new magnetic resonance (MR) innovations: SIGNA Sprint with Freelium, SIGNA Bolt, and SIGNA One. These next-generation MRI systems are designed to enhance efficiency, sustainability, and diagnostic accuracy, addressing rising demand and workforce constraints in radiology. The clearances reinforce GEHC's leadership in precision imaging and align with broader healthcare trends towards sustainability, automation, and operational efficiency.
GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio
GE HealthCare has secured FDA 510(k) clearance for three new MR innovations: SIGNA Sprint with Freelium, a 1.5T sealed MRI system; SIGNA Bolt, an advanced 3T MRI scanner; and SIGNA One, an AI-enabled workflow ecosystem. These advancements aim to address rising imaging volumes, workforce constraints, and sustainability needs in the radiology market. The new portfolio enhances efficiency, diagnostic accuracy, and sustainability, solidifying GE HealthCare's leadership in precision imaging and supporting long-term revenue growth.
AMN Q4 Earnings Meet Estimates, Revenues Beat, Gross Margin Contracts
AMN Healthcare Services, Inc. (AMN) reported Q4 2025 adjusted EPS of 22 cents, meeting analyst estimates, while revenues of $748.2 million surpassed expectations. Despite the revenue beat, the company experienced a significant year-over-year decline in EPS and a contraction in gross margin. AMN provided Q1 2026 revenue guidance of $1.225-$1.240 billion, driven largely by labor disruption revenues, and projects long-term organic revenue growth of 4-6% annually.
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
This article compares two MedTech companies, Boston Scientific (BSX) and Abbott (ABT), evaluating them as potential investments. It details each company's recent operational performance, strategic acquisitions, and financial metrics, including EPS estimates and price-to-sales ratios. While both are strong players in the MedTech sector with bullish analyst ratings, Abbott is presented as the more attractive option due to its current valuation and recent stock performance.
Cardio Diagnostics Unveils New AI-driven Platform as Market Anticipates Growth
Cardio Diagnostics Holdings Inc. (CDIO) saw its stock rise by 41.96% following news of advancements in its AI-driven precision cardiovascular testing platforms and an upcoming investor call. Despite promising developments in precision medicine with tests like Epi+Gen CHD and PrecisionCHD, the company faces financial strain with negative free cash flow. The market is keenly watching how these AI innovations will translate into tangible financial growth and improved profitability.
Kovack Advisors Inc. Has $2.33 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG
Kovack Advisors Inc. has significantly increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG), boosting its holdings by 382.1% in the third quarter to 5,211 shares, now valued at approximately $2.33 million. This increase comes alongside Intuitive Surgical exceeding Q3 earnings and revenue estimates. Despite this, company insiders have been net sellers, offloading over $30 million worth of shares in the past 90 days.
Intuitive Surgical, Inc. $ISRG Shares Acquired by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. significantly increased its stake in Intuitive Surgical (NASDAQ:ISRG) by 22.5% in the third quarter, now owning 11,463 shares valued at $5.13 million. This comes as Intuitive Surgical reported a strong quarterly beat with $2.53 EPS and revenue of $2.87 billion, an 18.8% year-over-year increase. Despite institutional buying, recent insider selling totaling $30.8 million occurred over the last 90 days.
Intuitive Surgical Stock at $500: What Is the Market Signaling?
Intuitive Surgical (ISRG) shares increased by 3% this week, reaching $501, driven by strong Q4 earnings, 18% global procedure growth, and renewed investor focus on 2026 procedure expansion. Analysts maintain positive ratings with price targets around $612, indicating confidence in long-term robotic surgery adoption despite a conservative 2026 outlook and competitive risks. The stock appears modestly undervalued for long-term investors, offering an implied 22% upside from its current level but facing risks from potential multiple compression.
ISRG Intuitive Surgical (NASDAQ) pre-market $499.53 on 20 Feb 2026: AI-enabled devices guide outlook
Intuitive Surgical (ISRG) trades pre-market at $499.53, slightly down, as investors weigh its leading position in robotic-assisted surgery against its premium valuation. Despite trading below its 50 and 200-day averages, the company maintains strong fundamentals and R&D investment in AI-driven healthcare. Meyka AI gives ISRG a "BUY" rating with a 12-month price target of $604.32, seeing significant upside potential amidst some short-term volatility and valuation concerns.
Robotic Surgical Systems Market Is Going to Boom | Intuitive
Coherent Market Insights has published a new research report on the Robotic Surgical Systems Market, forecasting substantial growth from 2026 to 2033. The report offers a deep dive into market trends, drivers, and competitive landscapes, featuring key players like Intuitive Surgical, Medtronic, and Johnson & Johnson. It provides comprehensive segmentation, regional analysis, and strategic insights for businesses in the healthcare sector.
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
Exact Sciences (EXAS) reported a net loss of 21 cents per share in Q4 2025, matching estimates, with revenues of $878.4 million beating the Zacks Consensus Estimate. Consolidated revenues for the full year reached $3.25 billion, an increase of 17.7%. The company saw strong revenue growth in both its Screening and Precision Oncology segments, though increased operating expenses led to a higher operating loss compared to the previous year.
Cardio Diagnostics Announces Investor Call Amidst Strategic Growth Plans
Cardio Diagnostics Holdings Inc. (CDIO) is holding an investor call to discuss strategic growth initiatives, including advancements in its AI-backed precision cardiovascular test. Despite reporting a net loss of $1.71M, the company maintains a robust 100% gross margin and a low debt-to-equity ratio of 0.03. The call aims to boost investor confidence and align narratives regarding the company's future in the evolving healthcare technology market.
ISRG's International Growth Outpaces US With 35% Procedure Volume
Intuitive Surgical (ISRG) is experiencing significant international growth, with procedures outside the US climbing 23% in 2025, outpacing its 15% domestic growth. This international expansion, driven by improved market access and training, now accounts for 35% of total global procedures. Other medtech companies like Medtronic and Abbott are also seeing international markets as key growth drivers, demonstrating a broader trend in the industry.
Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views?
This article analyzes whether Intuitive Surgical (ISRG) is a worthwhile investment based on Wall Street's bullish views. It highlights that while analysts give ISRG an average brokerage recommendation of 1.77 (approximating Strong Buy), investors should be wary of inherent biases in these ratings. The piece suggests using the Zacks Rank, a proprietary stock rating tool based on earnings estimate revisions, as a more reliable indicator for investment decisions.
Why Banner Health upgraded its surgical robot fleet
Banner Health has upgraded its entire fleet of Intuitive Surgical’s da Vinci Xi surgical robots to the new da Vinci 5 model, totaling 49 units. This move signifies a significant investment in advanced surgical technology by the healthcare provider. The article highlights this upgrade as a key development in medical devices.
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Insulet Corporation (PODD) reported strong fourth-quarter and full-year 2025 results, with adjusted EPS of $1.55 and revenues of $783.8 million, both surpassing Zacks Consensus Estimates. The company saw significant growth in Omnipod revenues, especially internationally, and expanded its gross and operating margins. Insulet also provided a positive outlook for full-year 2026 and the first quarter, projecting continued revenue growth.
PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Insulet Corporation (PODD) reported strong fourth-quarter and full-year 2025 results, with adjusted EPS and revenues surpassing Zacks Consensus Estimates. The company saw significant growth in Omnipod revenues, particularly internationally, and expanded its gross and operating margins. Insulet also provided a positive outlook for full-year 2026 and robust guidance for the first quarter, reflecting continued momentum in its business.
Is It Too Late To Consider Intuitive Surgical (ISRG) After Recent Share Price Weakness?
Intuitive Surgical (ISRG) has experienced recent share price weakness, with declines over the past month and year, despite strong long-term returns. Simply Wall St's valuation analysis suggests the stock is currently overvalued based on Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratios, giving it a valuation score of 1 out of 6. The article explores both bullish and bearish "Narratives" for ISRG's future, highlighting how different assumptions about growth and margins lead to varied fair value estimates.
Comgest Global Investors S.A.S. Sells 6,341 Shares of Intuitive Surgical, Inc. $ISRG
Comgest Global Investors S.A.S. significantly reduced its stake in Intuitive Surgical, Inc. by selling 6,341 shares, lowering its holdings by 43.6% to 8,211 shares valued at $3.67 million. Despite this, other institutional investors have recently increased their positions in the medical equipment provider. Intuitive Surgical reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating among analysts.
Axxcess Wealth Management LLC Cuts Stock Holdings in Intuitive Surgical, Inc. $ISRG
Axxcess Wealth Management LLC significantly reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 28.2% in the third quarter, selling 3,106 shares and holding 7,911 shares valued at $3.54 million. Despite this, other institutional investors like Norges Bank and Vanguard Group Inc. increased their holdings, with institutional ownership reaching 83.64%. The article also notes recent insider stock sales by company executives and analyst ratings, which currently give Intuitive Surgical a "Moderate Buy" consensus.
The 5 Most Interesting Analyst Questions From DexCom's Q4 Earnings Call
DexCom's Q4 2025 earnings call highlighted strong performance, driven by the G7 15-day sensor system and international expansion. Analysts focused on long-term growth prospects, Medicare coverage for type two non-insulin users, the G7 sensor's margin contributions, and factors influencing revenue growth guidance. Management expressed optimism about future expansion and continued high utilization rates.
Becton, Dickinson and Company (NYSE:BDX) Director Sells 953 Shares
Becton, Dickinson and Company (NYSE:BDX) Director Bertram Scott sold 953 shares of the company's stock for a total of $174,027.33, reducing his position by 2.53%. This sale occurred on February 18th, and details were filed with the SEC. After the transaction, Scott directly owns 36,763 shares valued at approximately $6.71 million.
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
Glaukos Corporation (GKOS) reported a Q4 2025 adjusted loss of 28 cents per share, missing estimates, despite revenues of $143.1 million surpassing expectations. The company provided optimistic 2026 guidance, expecting net sales between $600-$620 million, driven by strong adoption of iDose TR and the launch of Epioxa. Glaukos anticipates continued growth with ongoing investment in new platforms and pipeline developments, positioning itself for double-digit revenue expansion.
Drucker Wealth 3.0 LLC Has $943,000 Stake in Becton, Dickinson and Company $BDX
Drucker Wealth 3.0 LLC significantly reduced its stake in Becton, Dickinson and Company (BDX) by 62.9% in Q3, now holding 5,038 shares valued at $943,000, while institutional investors collectively own nearly 87%. BDX reported a quarterly earnings beat and provided 2026 EPS guidance, maintaining a consensus "Hold" rating from analysts with varying price targets. The company also declared a quarterly dividend of $1.05 per share and initiated a $10 million share buyback program.
Intuitive Surgical, Inc. $ISRG Shares Sold by Cercano Management LLC
Cercano Management LLC significantly reduced its stake in Intuitive Surgical (NASDAQ:ISRG) by 65.6% in the third quarter, selling 17,599 shares. Despite this, other institutional investors increased their holdings, and the company continues to show strong financial performance, beating quarterly earnings expectations with an 18.8% year-over-year revenue increase. Analysts maintain a "Moderate Buy" rating with an average target price of $617.23 for ISRG.
ISRG Intuitive Surgical (NASDAQ) pre-market +1.55% 18 Feb 2026: analysts’ targets
Intuitive Surgical (ISRG) saw a pre-market gain of 1.55% on February 18, 2026, after reporting strong Q1 2026 earnings, beating EPS and revenue estimates, driven by its da Vinci systems and AI-enabled diagnostics. Despite a rich valuation with a P/E of 62.69, analysts remain constructive with an average target of $617.23, and Meyka AI projects a 22.50% upside to $604.32, highlighting growth opportunities in digital tools but also risks from high valuation and insider selling. The company's next earnings report is scheduled for April 21, 2026.
Medtronic earns FDA clearance for Stealth AXiS spinal surgery system
Medtronic has received FDA clearance for its Stealth AXiS surgical system, an intelligent platform designed for spinal surgery with potential for future cranial and ENT applications. The system features LiveAlign segmental tracking, which provides real-time visualization of anatomic motion and adjustments without repeated imaging, aiming to improve surgical planning and execution. This technology is a cornerstone of Medtronic's MintegratesAiBLE smart ecosystem, intending to streamline workflows and connect devices, software, and data within spine surgery.
Medtronic completes first Hugo case in the US
Medtronic announced the first U.S. procedure using its Hugo robotic surgery system, a prostatectomy performed at Cleveland Clinic, following recent FDA clearance. CEO Geoff Martha stated that while Hugo might not significantly impact Medtronic's surgical business yet, its growth is rapid. Medtronic aims for Hugo to compete with Intuitive Surgical in soft tissue robotics and plans to expand indications beyond urology, while also reporting strong Q3 FY26 earnings with 8.7% overall revenue growth.
Medtronic completes first U.S. cases with Hugo
Medtronic has announced the successful completion of the first U.S. commercial cases utilizing its Hugo soft-tissue robotic surgery system. Dr. Jihad Kaouk of Cleveland Clinic performed a robotic-assisted prostatectomy, marking a significant step following FDA clearance for urologic procedures late last year. This move positions Medtronic to challenge Intuitive's longstanding dominance in the U.S. soft-tissue surgical robotics market, with CEO Geoff Martha expressing optimism about future expansions into additional indications.
Rep. Gilbert Ray Cisneros, Jr. Buys Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock
Representative Gilbert Ray Cisneros, Jr. (D-California) recently purchased between $1,001 and $15,000 worth of Intuitive Surgical, Inc. (NASDAQ:ISRG) stock on January 30th. This purchase comes as Intuitive Surgical exceeded earnings expectations, with its shares trading up and analysts maintaining a "Moderate Buy" rating. Despite significant insider selling over the past 90 days, institutional investors hold a substantial portion of the company's stock.
Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market
Labcorp (LH) reported Q4 2025 adjusted earnings per share of $4.07, surpassing the Zacks Consensus Estimate by 3% and rising 18% year-over-year. However, revenues of $3.52 billion missed estimates by 1%, causing the stock to decline slightly in pre-market trading. The company also provided its full-year 2026 revenue and adjusted EPS guidance, with both metrics aligning closely with Zacks Consensus Estimates.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx announced positive clinical validation data for AlloHeme, a new blood-based monitoring test designed to predict relapses in AML and MDS patients following allogeneic hematopoietic cell transplant. The ACROBAT study demonstrated AlloHeme's high diagnostic accuracy and ability to detect relapse earlier than traditional methods, supporting its commercialization beginning in 2027 as part of CareDx’s Transplant+ strategy. This advancement positions CareDx for growth in the cell therapy and hematologic oncology markets, expanding its precision medicine portfolio.
MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down
Medtronic plc (MDT) reported Q3 fiscal 2026 adjusted EPS of $1.36 and worldwide revenues of $9.02 billion, both surpassing Zacks Consensus Estimates. Despite this beat and organic revenue growth across its key segments, the company experienced contractions in gross and adjusted operating margins. Medtronic maintained its fiscal 2026 outlook, projecting organic revenue growth of 5.5% and adjusted EPS in the range of $5.62-$5.66.
Vanguard Group Inc. Increases Stock Position in Becton, Dickinson and Company $BDX
Vanguard Group Inc. has increased its stake in Becton, Dickinson and Company (BDX) by 0.5% in the third quarter, now owning 32,455,790 shares valued at approximately $6.07 billion, representing 11.32% of the company. Despite beating quarterly earnings expectations with $2.91 EPS and $5.25 billion in revenue, Becton, Dickinson and Company provided conservative FY2026 guidance below analyst estimates. The company declared a quarterly dividend of $1.05 and authorized a $10 million share repurchase plan, while analysts maintain a "Hold" rating with an average target price of $195.46.
NEOS Investment Management LLC Raises Holdings in Intuitive Surgical, Inc. $ISRG
NEOS Investment Management LLC significantly increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 60.5% in the third quarter, bringing its total holdings to 152,438 shares valued at $68.175 million. Other institutional investors also made purchases, contributing to 83.64% of the stock being owned by institutional investors and hedge funds. The company reported strong financial results, beating analyst expectations for both earnings per share and revenue, and analysts maintain a "Moderate Buy" consensus rating for ISRG.
What Price Targets Have Wall Street Analysts Set for Intuitive Surgical Shares?
Intuitive Surgical (ISRG) has underperformed the broader market, with its shares dropping significantly in the past year despite being a leader in robotic-assisted surgery. The company reported strong Q4 2025 earnings, with revenue up 19% year-over-year, driven by increased procedure volumes and da Vinci system placements. Analysts maintain a "Moderate Buy" rating, with an average price target indicating a 28.2% premium over current share prices.
Intuitive Surgical Stock: 2025 Q4 Results & 2026 Outlook - News and Statistics
Intuitive Surgical underperformed the broader market and healthcare equipment ETF despite strong Q4 2025 earnings, with revenue up 19% to $2.87 billion, driven by increased procedure volumes and da Vinci system placements. For 2026, the company forecasts 13-15% da Vinci procedure growth and analysts project a 13.9% rise in EPS to $8.22, maintaining a "Moderate Buy" consensus rating.
Glenview Trust Co Has $11.04 Million Stake in Becton, Dickinson and Company $BDX
Glenview Trust Co recently reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 31.8% in Q3, now owning shares worth $11.04 million. Despite this reduction, other institutional investors have increased their stakes. The company also announced a share repurchase program and a quarterly dividend of $1.05 per share.
PNC Financial Services Group Inc. Sells 2,193 Shares of Intuitive Surgical, Inc. $ISRG
PNC Financial Services Group Inc. reduced its stake in Intuitive Surgical, Inc. by 1.6% in the third quarter, selling 2,193 shares. Despite this, Intuitive Surgical reported strong financial results with an earnings beat and 18.8% year-over-year revenue growth. The article also highlights significant insider selling, with Director Gary Guthart selling 24,500 shares and overall insider sales reaching $30.8 million in the past 90 days.
Intragastric Balloons Market to Reach $115.3 Million, Globally, by 2033 at 13.6% CAGR: Allied Market Research
The global intragastric balloons market, valued at $32.2 million in 2023, is projected to reach $115.3 million by 2033, growing at a CAGR of 13.6%. This growth is primarily driven by rising obesity rates, increased preference for non-surgical weight-loss options, and technological advancements. Key market segments include single intragastric balloons, saline-filled balloons, and hospitals as the main end-users, with North America leading in utilization and Asia-Pacific showing rapid growth.
Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 Momentum
Medtronic (MDT) has transitioned from a stable but slow-moving company to a high-growth contender, driven by its revitalized cardiovascular portfolio and a successful "Medtronic Mindset" culture shift, as evidenced by its strong Q3 FY26 results. The company posted impressive organic revenue growth of 5.8% and expanded operating margins, while its robust product pipeline, including Pulsed Field Ablation and the Hugo RAS system, positions it to reclaim market share in key medical technology segments. Despite competitive and regulatory challenges, Medtronic's diversified portfolio, strong leadership, and focus on innovation provide a solid foundation for continued growth and an attractive dividend for investors.
What Price Targets Have Wall Street Analysts Set for Intuitive Surgical Shares?
Intuitive Surgical (ISRG) has underperformed the broader market, with its shares dropping significantly over the past year despite being a leader in medical technology. The company, which specializes in robotic-assisted surgical platforms, reported strong Q4 2025 earnings with revenue climbing 19% year-over-year, driven by increased procedure volumes and da Vinci system placements. Analysts maintain a "Moderate Buy" consensus rating for ISRG, with an average price target of $622.92, suggesting a 28.2% upside.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx recently announced positive clinical validation data for its AlloHeme blood test, designed to predict relapses in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplant (HCT). The ACROBAT study demonstrated AlloHeme's high sensitivity and specificity, detecting relapses earlier than standard methods. This development strengthens CareDx's expansion into cell therapy and hematologic oncology, with commercialization planned for 2027.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx recently announced positive clinical validation data for AlloHeme, a next-generation blood-based monitoring test designed to predict relapses in patients with AML and MDS following HCT. The ACROBAT study demonstrated AlloHeme's high diagnostic accuracy and ability to detect relapse earlier than standard methods, supporting the company's expansion into cell therapy and hematologic oncology. CareDx plans a phased U.S. rollout for AlloHeme, with commercialization expected by 2027.
Zions Bancorporation National Association UT Purchases 3,437 Shares of Intuitive Surgical, Inc. $ISRG
Zions Bancorporation National Association UT increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 24.7% during the third quarter, bringing their total holdings to 17,360 shares valued at $7.76 million. Other institutional investors also modified their positions. The article also details recent insider stock sales by EVP Myriam Curet and VP Fredrik Widman, and provides an overview of analyst ratings and the company's financial performance.
Vanguard Group Inc. Purchases 263,828 Shares of Intuitive Surgical, Inc. $ISRG
Vanguard Group Inc. increased its stake in Intuitive Surgical (NASDAQ:ISRG) by 0.8% in the third quarter, purchasing an additional 263,828 shares, bringing its total holdings to 33,599,661 shares valued at approximately $15.03 billion. This represents about a 9.37% ownership in the medical equipment provider. While institutional investors are increasing their positions, corporate insiders have been net sellers, divesting over 56,000 shares in the last 90 days.
3,555 Shares in Intuitive Surgical, Inc. $ISRG Bought by Mmbg Investment Advisors CO.
Mmbg Investment Advisors CO. has significantly increased its stake in Intuitive Surgical (NASDAQ:ISRG) by acquiring 3,555 shares valued at approximately $1.59 million during the third quarter. This move, alongside other institutional investors boosting their positions, brings the total institutional ownership of ISRG to 83.64%. The company recently reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating among analysts.
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down
Bruker Corporation (BRKR) reported Q4 2025 adjusted earnings that missed analyst estimates by 9.2%, falling 22.4% year over year, despite revenues slightly beating expectations. The company experienced contracting gross and operating margins due to lower volume, unfavorable mix, tariffs, and currency headwinds. Bruker provided 2026 guidance, projecting revenue growth of 4% to 5% and adjusted EPS growth of 15% to 17%.
ABN Amro Investment Solutions Trims Stock Position in Intuitive Surgical, Inc. $ISRG
ABN Amro Investment Solutions significantly reduced its stake in Intuitive Surgical, Inc. by 49.0% in Q3, selling 9,336 shares and retaining 9,727 shares valued at $4.35 million. Despite this, Intuitive Surgical outperformed quarterly estimates with strong EPS and revenue growth, leading analysts to maintain a "Moderate Buy" rating with an average $617.23 price target. However, company insiders have been net sellers, offloading shares worth approximately $30.8 million over the past 90 days.
ABN Amro Investment Solutions Sells 11,020 Shares of Zimmer Biomet Holdings, Inc. $ZBH
ABN Amro Investment Solutions recently reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 31.6%, selling 11,020 shares, and now holds 23,860 shares valued at approximately $2.35 million. This move comes as Zimmer Biomet reported strong quarterly results, surpassing EPS and revenue expectations, and provided encouraging FY2026 guidance. Despite ABN Amro's reduction, institutional interest remains high, with Rakuten Investment Management Inc. opening a significant new position.
